Cambrian BioPharma

Multiple (mitophagy, senescence, mTOR) · Multiple age-related

Phase 1Senolytics

Mechanism

Multiple (mitophagy, senescence, mTOR)

Intervention class

Holding co / multi-asset

Indication

Multiple age-related

Stage

Phase 1

Evidence

human

Funding

$160M+

Backers

Various

Overview

A 'DisCo' (distributed development) holding company spinning out single-asset subsidiaries against distinct aging hallmarks. Spreads the bet across mechanisms.

Technology

Cambrian BioPharma works in Senolytics — Drugs that hunt down and kill the 'zombie' cells that drive aging.

Read the Senolytics brief →

Related companies

Calico

Multiple (cellular senescence, neurodeg.)

Unity Biotechnology

Bcl-xL inhibition (senolytic)

Insilico Medicine

TNIK inhibition (anti-fibrotic / senescence)

Dorian Therapeutics

USP7 inhibition (senolytic)

Company website / source ↗ Open the interactive map →

◢ Boom-cycle briefing

Get ahead of the next biotech boom.

New companies, stage changes, deal alerts and fresh tech briefs — one sharp email when the map moves.

Curated biotech intelligence, compiled for orientation — not investment advice. Company stages, deals and figures move fast; verify against ClinicalTrials.gov, company filings and primary sources before acting.